Literature DB >> 18989658

Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific.

Brian C Jensen1, Philip M Swigart, Paul C Simpson.   

Abstract

Commercial antibodies are used widely to quantify and localize the alpha1-adrenergic receptor (AR) subtypes, alpha1A, alpha1B, and alpha1D. We tested ten antibodies, from abcam and Santa Cruz, using western blot with heart and brain tissue from wild-type (WT) mice and mice with systemic knockout (KO) of one or all three subtypes. We found that none of the antibodies detected a band in WT that was absent in the appropriate KO or in the KO that was null for all alpha1-ARs (ABDKO). We conclude that the antibodies we tested are not specific for alpha1-ARs. These results raise caution with prior studies using these reagents. For now, competition radioligand binding is the only reliable approach to quantify the alpha1-AR subtype proteins. Receptor protein localization remains a challenge.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18989658      PMCID: PMC2653258          DOI: 10.1007/s00210-008-0368-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

1.  alpha 1d Adrenoceptor signaling is required for stimulus induced locomotor activity.

Authors:  A Sadalge; L Coughlin; H Fu; B Wang; O Valladares; R Valentino; J A Blendy
Journal:  Mol Psychiatry       Date:  2003-07       Impact factor: 15.992

2.  Decreased blood pressure response in mice deficient of the alpha1b-adrenergic receptor.

Authors:  A Cavalli; A L Lattion; E Hummler; M Nenniger; T Pedrazzini; J F Aubert; M C Michel; M Yang; G Lembo; C Vecchione; M Mostardini; A Schmidt; F Beermann; S Cotecchia
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

Review 3.  Signal transduction and regulation: are all alpha1-adrenergic receptor subtypes created equal?

Authors:  Peter Hein; Martin C Michel
Journal:  Biochem Pharmacol       Date:  2006-11-07       Impact factor: 5.858

Review 4.  Clinical implications from studies of alpha1 adrenergic receptor knockout mice.

Authors:  Taka-aki Koshimizu; Akito Tanoue; Gozoh Tsujimoto
Journal:  Biochem Pharmacol       Date:  2006-11-07       Impact factor: 5.858

5.  Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.

Authors:  Timothy D O'Connell; Philip M Swigart; M C Rodrigo; Shinji Ishizaka; Shuji Joho; Lynne Turnbull; Laurence H Tecott; Anthony J Baker; Elyse Foster; William Grossman; Paul C Simpson
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

6.  The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries.

Authors:  Brian C Jensen; Philip M Swigart; Marie-Eve Laden; Teresa DeMarco; Charles Hoopes; Paul C Simpson
Journal:  J Am Coll Cardiol       Date:  2009-09-22       Impact factor: 24.094

7.  The alpha(1A/C)- and alpha(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse.

Authors:  Timothy D O'Connell; Shinji Ishizaka; Akihiro Nakamura; Philip M Swigart; M C Rodrigo; Gregory L Simpson; Susanna Cotecchia; D Gregg Rokosh; William Grossman; Elyse Foster; Paul C Simpson
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

8.  Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure.

Authors:  D Gregg Rokosh; Paul C Simpson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

  8 in total
  89 in total

1.  Commercially available antibodies against human and murine histamine H₄-receptor lack specificity.

Authors:  Silke Beermann; Roland Seifert; Detlef Neumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-10       Impact factor: 3.000

2.  Nuclear localization drives α1-adrenergic receptor oligomerization and signaling in cardiac myocytes.

Authors:  Casey D Wright; Steven C Wu; Erika F Dahl; Alan J Sazama; Timothy D O'Connell
Journal:  Cell Signal       Date:  2011-11-18       Impact factor: 4.315

Review 3.  Therapeutic antibodies directed at G protein-coupled receptors.

Authors:  Catherine J Hutchings; Markus Koglin; Fiona H Marshall
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

4.  Selection of recombinant anti-SH3 domain antibodies by high-throughput phage display.

Authors:  Haiming Huang; Nicolas O Economopoulos; Bernard A Liu; Andrea Uetrecht; Jun Gu; Nick Jarvik; Vincent Nadeem; Tony Pawson; Jason Moffat; Shane Miersch; Sachdev S Sidhu
Journal:  Protein Sci       Date:  2015-09-16       Impact factor: 6.725

5.  The Protein Acyl Transferase ZDHHC21 Modulates α1 Adrenergic Receptor Function and Regulates Hemodynamics.

Authors:  Ethan P Marin; Levente Jozsef; Annarita Di Lorenzo; Kara F Held; Amelia K Luciano; Jonathan Melendez; Leonard M Milstone; Heino Velazquez; William C Sessa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-12-29       Impact factor: 8.311

6.  Altered adrenergic receptor signaling following traumatic brain injury contributes to working memory dysfunction.

Authors:  N Kobori; B Hu; P K Dash
Journal:  Neuroscience       Date:  2010-10-23       Impact factor: 3.590

7.  Specificity concerns with antibodies for receptor mapping.

Authors:  Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2009-04       Impact factor: 84.694

8.  How reliable are G-protein-coupled receptor antibodies?

Authors:  Martin C Michel; Thomas Wieland; Gozoh Tsujimoto
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-27       Impact factor: 3.000

Review 9.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

10.  Six commercially available angiotensin II AT1 receptor antibodies are non-specific.

Authors:  Julius Benicky; Roman Hafko; Enrique Sanchez-Lemus; Greti Aguilera; Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2012-07-28       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.